Expanded Access Protocol (Eap) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming

Expanded Access Protocol (Eap) For Subjects Receiving Idecabtagene Vicleucel That Is Nonconforming
Recruiting
18 years - 99 years
All
Phase N/A
1 Location

Brief description of study

This study is designed to provide patients access to their nonconforming ide-cel as a treatment option for their disease. The study will evaluate the safety and effectiveness of this therapy through the collection of information. You may or may not receive direct medical benefit from participating in this study. The hope is that this study treatment may provide a new treatment option for patients with your disease, however, such a benefit cannot be guaranteed. There are no study specific procedures required for this study as you will receive routine medical care during the course of your participation. Results from these routine medical care procedures will be collected for research purposes.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: multiple myeloma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older, multiple myeloma has had idecabtagene vicleucel (ide-cel), for the treatment of your disease as part of routine care

Updated on 04 Aug 2024. Study ID: 849169

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center